elearning

Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Bookmark and Share

Neutropenia in Cancer Patients

This module is based on the latest scientific evidence for treating neutropenia. It focuses on how to improve outcomes for cancer patients with neutropenia and reduce the risk of infection by providing recommendations based on current guidelines and best practice.

Published December 2017.

Neutropenia in Cancer Patients
Module
English
1 CME Points

Target audience

This education is aimed at consultants and/or attending physicians involved in the assessment, management and prevention of cancer-related Neutropenia.

Learning objectives

By the end of this module you will be able to:

  • Define febrile neutropenia in cancer patients.
  • Identify risk levels for the development and management of febrile neutropenia.
  • Understand the infectious etiologies of neutropenia.
  • Manage the consequences of febrile neutropenia, including preventive measures.
  • Educate patients to recognise signs and symptoms of potential infection during neutropenia.

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure policy

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Amgen.

Support

Production of this module was funded by an unrestricted grant from Amgen.